Brought to you by 
GW Pharmaceuticals plc
https://www.gwpharm.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GW Pharmaceuticals plc
GW Pharma Among Myriad Hopefuls Seeking Extended Indications In EU
Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price
The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense.
UK Eases Access To GW's Cannabidiol Epilepsy Drug
The easing of the regulations governing GW Pharmaceuticals’ groundbreaking epilepsy drug in the UK will be followed by wider availability in Europe as pricing and reimbursement discussions continue.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Greenwich Biosciences, Inc.